Navigation Links
Sancilio and Company Announces New Directors

RIVIERA BEACH, Fla., July 23, 2012 /PRNewswire-iReach/ -- Sancilio and Company, Inc. (SCI) is pleased to announce the recent addition of Dr. Alan Dunton, Mr. Patrick Gray, Mr. Rod Jackson, Dr. Dennis Langer and Mr. Kelly Perkins to its Board of Directors.  The new directors join the Company's Chairman, Dr. Frederick Sancilio, who is also Founder, President and CEO.

"Our new directors are very well-known in the life sciences and financial industries.  Their outstanding credentials, recognized leadership, and depth of executive experience are evidence of SCI's commitment to attract the highest quality leadership available.  Each of our new directors is exceptionally well suited to help lead the Company into its next phase, and together will help grow our Company to new levels," said Dr. Sancilio.

SCI is a vertically integrated pharmaceutical company based in Riviera Beach, Florida focused on cardiovascular, dental and women's health products.  SCI's products include Ocean Blue® Professional Omega-3 2100™, chewable and liquid prescription sodium fluorides, and prescription prenatal vitamins.

New Director Profiles

Dr. Alan Dunton

Dr. Dunton has over 25 years of experience as an executive in the pharmaceutical/biotechnology industry.  Dr. Dunton is the founder and principal of Danerius, LLC, a consulting firm that works with small to mid-size pharmaceutical companies to guide them through drug development programs, assist them in identifying and evaluating product opportunities, and secure funding or partnering opportunities.

Prior to founding Danerius, Dr. Dunton held numerous positions in major pharmaceutical companies.  Most recently, he served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc., and previously served as President and CEO of Metaphore Pharmaceuticals.  Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including President and Managing Director of The Janssen Research Foundation.  Dr. Dunton also held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc.

Dr. Dunton serves on several boards of directors, including EpiCept Corporation, as Non-Executive Chairman, Targacept, Inc., Oragenics, Inc. and Palatin Technologies Inc. 

Dr. Dunton earned an MD from New York University School of Medicine and a BS in Biochemistry from State University School of New York at Buffalo.

Patrick Gray

Mr. Gray has 37 years of experience with PricewaterhouseCoopers in Boston, Philadelphia, New York, Vancouver and Florham Park, NJ, including 25 years as an Audit Partner.  During his time at PwC, Mr. Gray provided services across a range of industries, including life sciences, technology, services and industrial companies, and served clients that included Biogen, Genzyme, Millipore, Sepracor, BearingPoint, Oak Industries, Parametric Technology and Fisher Scientific.  From 1986 to 1997, Mr. Gray acted as leader and co-leader of the Price Waterhouse U.S. High Tech practice and from 2007 to 2009 led the PwC U.S. Corporate Governance Group. 

Mr. Gray earned a BS from The Wharton School of Business at the University of Pennsylvania and is a Certified Public Accountant.    

Roderick Jackson

Mr. Jackson has over 40 years of experience as an executive in the pharmaceutical/biotechnology industry, including 16 years with Mylan Laboratories.  Mr. Jackson joined Mylan in 1986 as Vice President of Marketing and Sales.  In 1992, Mr. Jackson was promoted to Senior Vice President where he was tasked with the creation of a new Business Development and Strategic Planning Department.  In this role, Mr. Jackson was responsible for creation of the Institutional and Branded Divisions of Mylan Laboratories.  Mr. Jackson was a member of Mylan's Office of the President and Executive Management Committee until his retirement in 2002.

In 2005, Mr. Jackson established Cobalt Laboratories, Inc., a U.S subsidiary of Arrow Group.  Under Mr. Jackson's leadership, Cobalt developed a product line and grew annual revenues to $200M.  In 2009, Arrow and Cobalt were sold to Watson Pharmaceuticals for $2.15B.

Mr. Jackson earned a BBA from Texas A&M Kingsville University.

Dr. Dennis Langer

Dr. Langer has over 25 years of experience in the pharmaceutical/biotechnology industry.  From 2005 to 2010, Dr. Langer served as a Managing Partner of Phoenix IP Ventures, a private equity and venture capital fund specializing in the pharmaceutical sector.   Previously, Dr. Langer served as President, North America, of Dr. Reddy's Laboratories Limited.   From 1994 to 2004, Dr. Langer held several positions at GlaxoSmithKline, including Senior Vice President of Research and Development.  Prior to GlaxoSmithKline, Dr. Langer held numerous positions in innovative research and development companies such as Eli Lilly, Abbott and GD Searle.  Earlier in his career, he was Chief Resident in Psychiatry at Yale University School of Medicine and held clinical fellowships in Psychiatry at Harvard Medical School, George Washington University School of Medicine, and the National Institutes of Health. 

Dr. Langer serves on several boards of directors, including Myriad Genetics, Inc., Myrexis, Inc., and Dicerna Pharmaceuticals, Inc., and is an Advisor to Investor Growth Capital.  Dr. Langer is a Clinical Professor in the Department of Psychiatry, Georgetown University School of Medicine. 

Dr. Langer earned an MD from Georgetown University School of Medicine, a JD from Harvard Law School, and a BA in Biology from Columbia University.

Kelly Perkins

Mr. Perkins is an original Principal, Executive Committee Member and Co-Chief Investment Officer of Lighthouse Partners, a West Palm Beach-based manager of funds of hedge funds.  Lighthouse has approximately $5.9 billion under management for institutional and private investors.  Previously, Mr. Perkins held several positions at Bermuda-based Trout Trading Management Company, Ltd., including Director of Accounting.  Prior to joining Trout, Mr. Perkins served as a business associate with Coopers & Lybrand, LLP. 

Mr. Perkins earned a BBA in Accounting from the College of William and Mary and is a Chartered Financial Analyst.

About Sancilio and Company, Inc.

Sancilio and Company, Inc. is a vertically integrated pharmaceutical company focused on the development, manufacture and sale of cardiovascular, dental and women's health products.  SCI's products include Ocean Blue® Professional Omega-3 2100™, which contains 2,100 mg of Omega-3 per serving, chewable and liquid prescription sodium fluorides, and prescription prenatal vitamins.  SCI's research and development labs and manufacturing facilities are all located in Riviera Beach, Florida.

Additional information about SCI can be found on the web at and    

Media Contact: Daren Graham, Chief Legal Officer Sancilio and Company, Inc., (561) 209-2834,

News distributed by PR Newswire iReach:

SOURCE Sancilio and Company, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
2. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
3. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
4. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
5. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
6. DiversityInc Names Lilly a Top Company for Diversity
7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
8. The Female Health Company Reports Second Quarter Operating Results
9. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
10. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
11. Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager
Post Your Comments:
(Date:1/24/2017)... For today, scans the following Biotechnology companies: ... Inc. (NASDAQ: ALDR ), BioDelivery Sciences International Inc. ... EGLT ). These equities are part of the Healthcare ... , 2017, with the NYSE Health Care Index dropping about ... 500 also were down 0.3% as a group. These stocks ...
(Date:1/24/2017)... YORK , Jan. 23, 2017 ... long way from conventional syringes with vials to ... systems. These modern devices have become preferred devices ... for prefilled syringes has been rising strongly over ... healthcare facilities are now adopting this format for ...
(Date:1/24/2017)... 2017 The global peripheral I.V. catheter market ... is expected to grow at a CAGR of 6.0% ... for larger share in the global market between the ... users, the hospital segment accounted for the highest share ... global peripheral I.V. catheter market is witnessing high growth ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... ... With God’s Voice”: a resolute and spirited call for anointed preaching in today’s ... a born-again believer, who spent his years teaching high school and Sunday-school, and continues ... little doubt that God Himself prepared me for this study, and God’s messengers who ...
(Date:1/24/2017)... , ... January 24, 2017 , ... “Mysteries Revealed On ... be a mysterious phenomenon is available to all Christians. “Mysteries Revealed On Speaking In ... of “U Beautiful Creation,” a Christian-based talk show located in Michigan. , “We ...
(Date:1/24/2017)... ... January 23, 2017 , ... CLICKco LLC, a company known ... its CLICK® Coffee Protein Drink is now available for purchase on, a ... popular among health-conscious consumers who love coffee but are looking to add more ...
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue of the Journal of ... how outdoor behavioral healthcare (OBH) – also known as wilderness therapy – helped a ... an increased sense of purpose both during and after treatment. , The study ...
(Date:1/24/2017)... , ... January 23, 2017 , ... ... of a new plugin that allows sleep centers to automatically connect and initialize ... (SDI)—is a thin client browser plugin is quickly installed on first use and ...
Breaking Medicine News(10 mins):